INTERACT2 (Intensive Blood Pressure Reduction In Acute Cerebral Haemorrhage Trial) is the main phase of an academic led and conducted, international, multi-centre, open label, blinded endpoint, randomised controlled trial to establish the balance of benefits and risks of a treatment strategy of early intensive lowering of blood pressure (BP) compared to a conservative BP lowering policy in patients with acute primary intracerebral haemorrhage (ICH) and co-existing elevated BP without any definite indication or contraindication to treatment.
INTERACT2 in India
Approximately 20 participating private and government hospitals will aim to recruit 600 patients (20% of the total randomised participants) to this important trial. Patient recruitment in India will start in the second half of 2009.
Collaborators
INTERACT2 Country Principal Investigator:
Dr K Subash
Nizam’s Institute of Medical sciences
